CYP19A1 and endometrial cancer: Although conventional endocrine treatments, including progesterone, gonadotropin-releasing hormone agonists and aromatase inhibitors demonstrate efficacy in endometrial cancer, their long-term utility is limited by adverse effects such as drug resistance and disease recurrence with prolonged treatment.